GB004 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	2

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-002306-12-PL (EUCTR)	12/01/2021	08/09/2020	GB004 in adult subjects with active ulcerative colitis	A Phase 2, randomized, double-blind, placebo-controlled, multi-center study to evaluate GB004 in adult subjects with mild-to-moderate active ulcerative colitis	Mild-to-moderate active ulcerative colitis MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: GB004 INN or Proposed INN: Not applicable Other descriptive name: GB004-HCl Product Code: GB004 INN or Proposed INN: Not applicable Other descriptive name: GB004-HCl	GB004, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	195	Phase 2	United States;Serbia;Belarus;Poland;Ukraine;Romania;Australia;Russian Federation;Georgia;Italy;Moldova, Republic of;Korea, Republic of
2	NCT03860896 (ClinicalTrials.gov)	April 24, 2019	14/2/2019	GB004 in Adult Subjects With Active Ulcerative Colitis	A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GB004 in Adult Subjects With Active Ulcerative Colitis	Ulcerative Colitis	Drug: GB004;Drug: Placebo	GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	NULL	Completed	18 Years	74 Years	All	34	Phase 1	United States;Georgia;Moldova, Republic of